Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors
Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer,…
22/07/2015 - 3 minutes
CAR-T
Theravectys’ HIV Cure on the Road to Success
Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic…
20/07/2015 - 3 minutes
How Servier saved Cellectis, the French CAR-T Miracle
Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration…
15/07/2015 - 5 minutes
Video: Discover How CAR-T Therapies are Working
It's becoming a habit for us to talk about CAR-T therapies. It's basically the next…
25/06/2015 - 1 minute
Celyad, the new face of Cardio3, is launching an IPO on NASDAQ
[UPDATE 19/06/2015]: Yesterday, Celyad launched its IPO on NASDAQ and the closing is expected to occur…
19/06/2015 - 2 minutes
[Update] AstraZeneca to buy a CAR-T expert?
[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca's CEO Pascal…
04/06/2015 - 3 minutes
Pfizer to Control Cellectis in a €1.5 Billion Deal?
Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer…
29/05/2015 - 2 minutes
[UPDATE] Adaptimmune raised €156.7M in its IPO
Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company…
13/05/2015 - 2 minutes
US-based Juno Therapeutics purchased a German biotech
Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich…
12/05/2015 - 2 minutes
Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T
Just a week after announcing its intention to launch an IPO in the United States,…
08/04/2015 - 2 minutes
Gene editing to make French fries less unhealthy
A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an…
06/04/2015 - 4 minutes
Merck Serono and Intrexon, to develop CAR-T Therapy
Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic…
31/03/2015 - 2 minutes
